EL7.AI
StocksHigh ImpactUpdated•Originally published 3 March 2026•Updated 3 March 2026•
1 min read

Theravance Biopharma Shares Plunge 26% as Company Explores Sale Following Trial Failure

Key Facts

1The Phase 3 CYPRESS study evaluating ampreloxetine failed to meet its primary endpoint in patients with symptomatic neurogenic orthostatic hypotension (nOH).
2The board is accelerating a strategic review and announced an organizational restructuring to reduce the cost base by approximately 60% (around $70 million).
3The company expects a cash balance of approximately $400 million by the end of Q1 2026, shifting focus to its growing COPD product, YUPELRI.

Theravance Biopharma (TBPH) shares plummeted 26% in morning trading following news that its Phase 3 CYPRESS study for ampreloxetine failed to meet its primary endpoint. The trial was specifically evaluating the drug's efficacy in patients with multiple system atrophy (MSA), a rare neurological condition. In response to the clinical setback, the company has engaged Lazard to explore a potential sale of the business as part of an accelerated strategic review. Concurrent with these efforts, Theravance is implementing a major restructuring plan aimed at reducing its cost base by 60%, or approximately $70 million annually. The company will now pivot its focus toward its commercial product YUPELRI to drive cash flow while maintaining a projected cash balance of $400 million by Q1 2026. This strategic shift highlights the company's urgent need to preserve capital and maximize the value of its remaining assets after losing a key growth catalyst.